Rectal Tumour Clinical Trial
Official title:
CHEMORADIOTHERAPY FOR RECTAL CANCER IN THE DISTAL RECTUM FOLLOWED BY ORGANSPARING TRANSANAL ENDOSCOPIC MICROSURGERY: CARTS Study CApecitabine, Radiotherapy and Tem Surgery. A PHASE II, FEASIBILITY TRIAL
In the Netherlands approximately 2300 new patients are diagnosed with rectal cancer each
year. Standard treatment for patients with a T2 or T3 rectal cancer consists of preoperative
short course of radiotherapy followed by surgery. In advanced cases long course of
radiotherapy combined with chemotherapy is used instead of a short cause. In some of these
advanced cases a complete remission is observed after a long course of radio-/chemotherapy.
Patients who respond well to neo-adjuvant treatment carry a better prognosis.
Objective of this research is to evaluate whether neo-adjuvant chemo-/radiotherapy in small
non-advanced rectal cancers can be used to obtain a complete or near complete remission. In
these patients could a complete resection of the rectum as an organ be avoided by treating
them with a local excision with the TEM-technique (Transanal Endoscopic Microsurgery) of the
scar. The advantage for these patients is, that they do not need major abdominal surgery and
in a substantial number of these patients the rectum can be preserved with a better function
of continence.
n/a